Nivolumab is a programmed death 1 (PD-1) inhibitor approved by the Food and Drug Administration (FDA) for the treatment of eight different cancers including metastatic melanoma. Immune checkpoint blockade may lead to a range of neurologic immune-related adverse events (irAEs) with severity varying from mild to life-threatening, including encephalitis.
Case report
We describe a case of a 68-year-old man who developed alteration in mental status, physical weakness and fatigue after nine cycles of nivolumab 3 mg/kg every two weeks. These symptoms were compatible with a clinical diagnosis of autoimmune limbic encephalitis, although no specific antibodies were detected and the initial MRI was normal.
Management and outcome
The patient received intravenous methylprednisolone 1 g daily for 5 days, which was then converted to a maintenance dose of oral prednisone. The patient made a full clinical recovery but relapsed clinically upon steroid tapering, while hypersignal in the left mesial temporal suggestive of limbic encephalitis was observed on repeated MRI.
Discussion
Because of the prevailing usage of nivolumab in many cancer protocols, this case highlights the importance of rapidly recognising neurological impairment in patients treated with nivolumab and of initiating very high doses of corticosteroids.
BrahmerJRHammersHLipsonEJ.Nivolumab: targeting PD-1 to bolster antitumor immunity.Future Oncol2015;
11: 1307–1326.
4.
AnsellSGutierrezMEShippMA, et al.
A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). Blood2016;
128: 183–183.
5.
BorghaeiHPaz-AresLHornL, et al.
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.N Engl J Med2015;
373: 1627–1639.
6.
WolchokJDChiarion-SileniVGonzalezR, et al.
Overall survival with combined nivolumab and ipilimumab in advanced melanoma.N Engl J Med2017;
377: 1345–1356.
7.
TimmermanJMEngertAYounesA, et al.
CheckMate 205 Update with minimum 12-month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood2016;
128: 1110–1110.
8.
GrausFTitulaerMJBenselerS, et al.
A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol2016;
15: 391–404.
HermetterCFazekasFHochmeisterS.Systematic review: syndromes, early diagnosis, and treatment in autoimmune encephalitis. Front Neurol2018;
9: 706.
11.
YangJMansonDKMarrBP, et al.
Treatment of uveal melanoma: where are we now?Ther Adv Med Oncol2018;
10: 1–17.
12.
FriedmanCFProverbs-SinghTAPostowMA.Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review.JAMA Oncol2016;
2: 1346–1353.
LarkinJChmielowskiBLaoCD, et al.
Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis.Oncologist2017;
22: 709–718.
15.
RichardKWeslowJPorcellaSL, et al.
A case report of steroid responsive nivolumab-induced encephalitis.Cancer Control2017;
24: 1–3.
De HolandaNCde LimaDDCavalcantiTB, et al.
Hashimoto’s encephalopathy: systematic review of the literature and an additional case.J Neuropsychiatry Clin Neurosci2011;
23: 384–390.
RapisuwonSIzarBBatenchukC, et al.
Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors. J Immunother Cancer2019;
7: 61.
21.
ChanPYHallPHayG, et al.
A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity.Pigment Cell Melanoma Res2017;
30: 558–562.
22.
HepptMVHeinzerlingLKählerKC, et al.,
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.Eur J Cancer2017;
82: 56–65.
23.
BrahmerJRLacchettiCSchneiderBJ, et al.
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol2018;
36: 1714–1768. 15.
24.
WilliamsTJBenavidesDRPatriceKA, et al.
Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer.JAMA Neurol2016;
73: 928–933.
25.
NaranjoCABustoUSellersEM, et al.
A method for estimating the probability of adverse drug reactions.Pharmacol Ther1981;
30: 239–245. 17.
26.
ThompsonJA.New NCCN guidelines: recognition and management of immunotherapy-related toxicity.J Natl Compr Canc Netw2018;
16: 594–596.
27.
HaanenJBAGCarbonnelF, et al.
Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol2017;
28: iv119–iv142.
28.
MatsuokaHKimuraHKobaH, et al.
Nivolumab-induced limbic encephalitis with anti-Hu antibody in a patient with advanced pleomorphic carcinoma of the lung.Clin Lung Cancer2018;
19: e597–e599.
29.
BurkeMHardestyMDownsW.A case of severe encephalitis while on PD-1 immunotherapy for recurrent clear cell ovarian cancer.Gynecol Oncology Rep2018;
24: 51–53.
30.
KazandjianDSuzmanDLBlumenthalG, et al.
FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy.Oncologist2016;
21: 634–642.
